Drugs · acquisition-cost intelligence
gabapentin
· ingredient gabapentin· GABAPENTIN 300 mg/1; GABAPENTIN 450 mg/1; GABAPENTIN 600 mg/1; GABAPENTIN 750 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$1.16
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other gabapentin products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| gabapentin | $0.03246 | −$1.13 |
| gabapentin | $0.06824 | −$1.10 |
| gabapentin | $0.08386 | −$1.08 |
| Gabapentin | $0.09799 | −$1.07 |
| GABARONE | $8.52 | +$7.35 |
| Gralise | $10.20 | +$9.03 |
| Horizant | $17.92 | +$16.75 |
Medicare Part D coverage · CY2026
On 32 plan formularies · typical tier 4
Prior auth 88% · Step therapy 0% · Quantity limit 97% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.